
Anthony King
I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.
My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.
I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.
My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.
- Business
New type of painkiller approved in US
Sodium channel blocker prevents nerves transmitting pain signals
- Research
Mapping metabolite disturbances by drugs
High-throughput metabolomic profiling gives insight into unpredictable drug effects
- Research
Life’s ingredients discovered in samples Nasa probe returned from an asteroid
Asteroid Bennu found to contain nucleobases, amino acids and ammonia
- Feature
Low concentration chemicals spur toxicological debate
Improved analytical techniques mean tiny amounts of endocrine disrupting compounds or PFAS can be found in many places. But is it a problem? Anthony King talks to the scientists on both sides of the fence
- Business
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025
£15 billion deal for neuroscience biotech aims to replace revenues from patent expiries
- Research
Mutant moulds threaten newest antifungal drugs putting immunocompromised patients at risk
Agrichemical antifungal use is leading to fungi that can evolve resistance to novel drugs faster – even those not even on the market yet
- Research
mRNA therapy might one day treat deadly pre-eclampsia in pregnant women
Therapy helped pregnant mice to regrow placental blood vessels
- Business
Opposition to lithium mines hampers green technology supply chain
Europe and US seek to escape Chinese dominance in critical minerals
- Business
Northvolt bankruptcy dents European battery industry ambitions
Swedish startup aimed to challenge Asian producers, but stumbled in scaling production
- Business
Europe reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
- Research
The race to commercialise nuclear-powered batteries
‘Radiovoltaic’ devices can deliver long-lasting power to pacemakers, planetary rovers and more
- Research
Meteorite 200 times larger than one that killed dinosaurs reset early life
Counterintuitively, impact brought benefits too by providing microorganisms with iron and phosphorus
- Business
Adnoc to buy Covestro, continuing expansion into polymers
€15 billion deal sees Gulf oil producer looking to future growth beyond fuels
- Business
Drug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
- Business
US approves schizophrenia drug with new mode of action
Cobenfy promises to better address negative symptoms than existing antipsychotics
- Business
UK’s Grangemouth refinery will close in 2025
Petroineos will convert site into a fuel import terminal with loss of 400 jobs
- Research
Therapeutic proteins can hitch a ride on parasite to bypass blood-brain barrier
Toxoplasma could be delivery agent for protein drugs – provided parasite can be made safe
- Business
Weight-loss drugmakers bet billions on boosting supplies
Eli Lilly and Novo Nordisk invest to expand in-house manufacturing of GLP-1 drugs
- News
Metallic nodules sought by deep sea miners could be making oxygen in the depths
Water-splitting at the bottom of the Pacific holds intriguing implications for the origin of life on Earth – and further afield
- Research
New gene-editing tool found in bacterium could carry out extensive genome remodelling
Highly selective mechanism can insert, remove and flip large portions of DNA